Skip to main content
. 2014 Dec 22;125(8):1236–1243. doi: 10.1182/blood-2014-08-595801

Table 2.

Duration of response per the investigator following treatment with brentuximab vedotin

All patients (N = 102)
Objective response according to the investigator, n (%) 73 (72)
 CR, n (%) 34 (33)
 PR, n (%) 39 (38)
Duration of response for patients with CR, months
 Median NE
 95% CI 20.5, NE
Duration of objective response, months
 Median 11.2
 95% CI 7.7, 18.7

Duration of response is calculated from the earliest occurrence of either CR or PR.

NE, not estimable.